Name: Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody
Brand: Syd Labs
SKU: C063P
Price: 175.00 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No.

Product Name

Size

List Price (US$)

Quantity

C063P

Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody

1 mg

175.00

C063P

Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody

5 mg

600.00

C063P

Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody

20 mg

1200.00

Description

Ruplizumab Biosimilar uses the same protein sequences as the therapeutic antibody ruplizumab.

Ruplizumab is a humanized anti-CD40L/CD154 monoclonal antibody. he binding of CD40 to its ligand, CD40L, is a critical element in T cell activation. In systemic lupus erythematosus, CD40L is over-expressed on T cells, B cells, and monocytes. It was intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis, as well as the primary skin allograft rejection. A study showed that the drug was associated with life-threatening thromboembolisms, while another study only found thrombocytopenia. In previous studies, the monoclonal antibody, ruplizumab showed evidence of potential efficacy in patients with lupus nephritis and idiopathic thrombocytopenic purpura. Besides, clinical trials were halted because of a higher than expected occurrence of thromboembolic events. It is proposed that the observed treatment-related (TR) thromboembolic events occurred as a result of platelet activation and aggregation, due to the formation of anti-CD40L antibody and soluble CD40L immune complexes that tether to platelets via binding of sCD40L to surface-expressed CD40 and activate platelets through interactions of the Fc with Fc gamma receptor IIA on the platelet surface.

Modern allotransplantation requires the daily administration of nonspecific immunosuppressive agents to prevent T cell-mediated acute rejection. The agents commonly used include glucocorticosteroids, antiproliferative agents such as azathioprine or mycophenolate mofetil (MMF) and calcineurin inhibitors (tacrolimus or cyclosporine A). Although these agents have considerably improved the outcome of patients receiving solid organ transplants, their therapeutic effects are transient, and all are associated with substantial toxicity. The CD40 ligand (CD40L, also known as CD154) has been shown to be an important modulator of immunoinflammatory events in autoimmune disease and acute allograft rejection. CD40 is expressed constitutively on antigen presenting cells (APCs), including B cells, while CD40L is a member of the tumor necrosis factor family of transmembrane glycoproteins and is expressed on activated CD4? T cells. The CD40-CD40L interaction is essential for normal T cell?B-cell interactions, including T-cell priming, immunoglobulin (Ig) class-switching, and the T cell-dependent humoral immune response. Indeed, the CD40-CD40L molecules form a co-stimulatory pair, providing the second signal required for T-cell activation of APCs. CD154 binds to CD40 and leads to APC secretion of IL-1?, TNF-?, and IL-12, and to endothelial cell secretion of monocyte chemotactic factors. It also increases APC and endothelial cell expression of MHC class II molecules, of adhesion molecules, and of the co-stimulatory ligands CD80 and CD86. Although blockade of the CD154-CD40 pathway does little to prevent the proliferative response of CD4+ T cells in vitro, it substantially curtails the maturation of cytotoxic CD8+ T cells by interfering with required T-cell-APC interactions. The monoclonal antibody ruplizumab neutralizes CD40L function, as it blocks the interaction between CD40 and CD40L. It has been proven in animal experiments that this drug can prolong rhesus monkey renal allograft survival.

C063P: Ruplizumab Biosimilar (Research Grade), Anti-human CD40L Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Source: The anti-human CD40L monoclonal antibody ruplizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade ruplizumab biosimilar specifically binds to the human CD40L.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ruplizumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: <1 EU/mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade pateclizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Syd Labs also provides the following anti-CD40 / CD40L antibody biosimilar proteins:
Toralizumab Biosimilar, research grade, anti-human CD40/CD40L/CD154 monoclonal antibody

Syd Labs provides the following in vivo grade recombinant human IgG1 kappa isotype control antibody proteins and mutants:
In vivo grade recombinant human IgG1 isotype control antibody
In vivo grade recombinant human IgG1 Fc protein
In vivo grade recombinant human IgG1-D265A isotype control antibody
In vivo grade recombinant human IgG1-N297A isotype control antibody
In vivo grade recombinant human IgG1-D265A N297A isotype control antibody
In vivo grade recombinant human IgG1-L234A L235A P329G (LALAPG) isotype control antibody

Home

Services

Molecular Biology

Proteins & Peptides

Antibodies

ELISA Kits

Chemicals

Cell Biology

Contact

My Syd Labs

Email Notifications

Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody

TNFSF5, CD154, CD40 ligand, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L

Note

Note

Order Offline